

Lesotho Support for Pentavalent Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Lesotho						
2. Grant number: 1922-LSO-04c-X; 08-LSO-08b-Y						
3. Date of Decision Letter: 12 March 2019						
4. Date of the Partnership Framework Agreement: 30 November 2012						
5. Programme title: New Vaccine Support (NVS), Pentavalent Routine						
6. Vaccine type: Pentavalent						
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 10 dose(s) per vial, LIQUID						
8. Programme duration¹: 2008 -2022						
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)						
	2008-2018	2019	2020	2021	2022	Total ²
Programme Budget (US\$)	2,454,282 ³	61,500	82,500	82,500	81,000	2,761,782
10. Vaccine introduction grant (in US\$) US\$ 100,00 was disbursed on 5 February 2008						
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴						
Type of supplies to be purchased with Gavi funds in each year	2008-2018	2019				
Number of Pentavalent vaccines doses		86,000				
Annual Amounts (US\$)	US\$2,454,282 ⁵	US\$61,500				
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.						
13. Self-procurement: Not applicable.						

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

14. Co-financing obligations: Reference code: 1922-LSO-04c-X-C

According to the co-financing policy, the Country falls within the group Preparatory transition.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2019	2020	2021	2022
Number of vaccine doses	8,500	12,500	15,000	17,000
Number of AD syringes	7,000	11,700	13,600	15,700
Number of safety boxes	100	150	175	175
Value of vaccine doses (US\$)	US\$5,550	US\$8,613	US\$10,062	US\$11,617
Total co-financing payments (US\$) (including freight)	US\$6,500	US\$9,500	US\$11,000	US\$13,000

15. Additional reporting requirements: Not applicable

Reports and information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2019 15 May 2019
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

16. Financial clarifications: Not applicable

17. Other conditions:

The country is reminded of its obligations under the PFA in respect of insurance and is requested to provide information to Gavi on the steps it has taken in this regard.

Signed by,



On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

12 March 2019